{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92"},{"groupId":"OG001","value":"0.83"}]}],"title":"Proportion with reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65"},{"groupId":"OG001","value":"0.40"}]}],"title":"Proportion with reduction > 30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43"},{"groupId":"OG001","value":"0.11"}]}],"title":"Proportion with reduction > 50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18"},{"groupId":"OG001","value":"0.09"}]}],"title":"Proportion with reduction > 75%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Proportion with depth of response (or tumour shrinkage or change in tumour size)","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Proportion of participants"}